Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Vergara Cadavid J"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tahri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Piccinelli S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Lampe L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Medical Department, Christian-Albrechts University, Kiel, Germany., Dong H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Vergara Cadavid J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Boiarsky R; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA., Papazian N; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Cao A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA., Alberge JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Ferrari de Andrade L; Precision Immunology Institute, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai Hospital, New York, NY., Rahmat M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Shen Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cancer Science Institute of Singapore, National University of Singapore Cancer Science, Singapore, Singapore.; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Blanco Fernández L; Clínica Universidad de Navarra, Center for Applied Medical Research, CIBERONC, IDISNA, Pamplona, Spain., Zabaleta A; Clínica Universidad de Navarra, Center for Applied Medical Research, CIBERONC, IDISNA, Pamplona, Spain., Günther A; Medical Department, Christian-Albrechts University, Kiel, Germany., Getz G; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Krantz Family Center for Cancer Research and Deptartment of Pathology, Massachusetts General Hospital, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA., Sonneveld P; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Cupedo T; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Romee R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.
Publikováno v:
Blood advances [Blood Adv] 2024 Oct 22; Vol. 8 (20), pp. 5365-5370.
Autor:
Shapiro RM; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Birch GC; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Hu G; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Vergara Cadavid J; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Nikiforow S; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Baginska J; Center for Immuno-oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Ali AK; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Tarannum M; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Sheffer M; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Abdulhamid YZ; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Rambaldi B; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.; University of Milano-Bicocca, Monza, Italy., Arihara Y; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Reynolds C; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Halpern MS; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Rodig SJ; Department of Pathology and., Cullen N; Department of Pathology and., Wolff JO; Department of Pathology and., Pfaff KL; Department of Pathology and., Lane AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Lindsley RC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Cutler CS; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Antin JH; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Ho VT; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Koreth J; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Gooptu M; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Kim HT; Department of Data Science, Dana-Farber Cancer Institute/Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA., Malmberg KJ; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Institute for Clinical Medicine, The University of Oslo, Oslo, Norway.; Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Solna, Sweden., Wu CJ; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Chen J; Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Soiffer RJ; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Ritz J; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Romee R; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Publikováno v:
The Journal of clinical investigation [J Clin Invest] 2022 Jun 01; Vol. 132 (11).